NGF mRNA is not decreased in frontal cortex from Alzheimer's Disease patients

N. Jetté, M. S. Cole, M. Fahnestock

Research output: Contribution to journalArticlepeer-review

67 Scopus citations

Abstract

Alzheimer's disease (AD) is characterized by neuronal dysfunction and degeneration in certain brain regions such as cortex, hippocampus and basal forebrain. Specific neurochemical defects such as decreases in cholinergic enzymes and in the amounts of mRNA in AD brain have also been reported. Nerve growth factor (NGF), a protein necessary for the development, regulation and survival of basal forebrain cholinergic neurons (BFCN), is synthesized in target areas of BFCN (cortex, hippocampus) and is supplied to BFCN by retrograde transport. Thus, NGF is under investigation both as a potential therapeutic agent and for its possible involvement in the pathogenesis of AD. In this study, postmortem brain tissues from both control and AD cases were investigated for amounts of poly (A)+ mRNA and NGF mRNA in the frontal cortex, a region rich in cholinergic afferents. Yields of poly(A)+ mRNA were similar from normal and AD tissues. Human NGF mRNA comigrated with murine NGF mRNA on Northern blots. Additionally, dot blot quantitation demonstrated that NGF mRNA levels do not differ in the inferior frontal gyrus of normal and AD patients. Thus, we conclude that levels of mRNA in general, and of NGF mRNA in particular, are unchanged in the frontal cortex of individuals affected by AD.

Original languageEnglish
Pages (from-to)242-250
Number of pages9
JournalMolecular Brain Research
Volume25
Issue number3-4
DOIs
StatePublished - Sep 1994
Externally publishedYes

Keywords

  • Densitometry
  • Dot blotting
  • Inferior frontal gyrus
  • Nerve growth factor
  • Northern blotting
  • Phosphorimage analysis
  • Postmortem interval
  • mRNA yields

Fingerprint

Dive into the research topics of 'NGF mRNA is not decreased in frontal cortex from Alzheimer's Disease patients'. Together they form a unique fingerprint.

Cite this